Diabetes
Discover unique market-leading data and insights into the Diabetes market. From the latest Diabetes industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Diabetesmarket reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Sector Analysis
Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
$14,995 | December 2024 This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033. GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period. Major drivers of T1D market growth over...
-
Sector Analysis
Type 1 Diabetes Epidemiology Analysis and Forecast to 2033 Type 1 Diabetes Epidemiology Analysis and Forecast to 2033
$3,995 | November 2024 Type 1 Diabetes Epidemiology Report Overview In the 7MM, there were 3,012,498 diagnosed prevalent cases of Type 1 Diabetes Epidemiology in 2023. The market will register an AGR of less than 1% during 2023-2033. Type 1 diabetes (T1D), formally referred to as insulin-dependent diabetes or juvenile diabetes, is a chronic autoimmune disease that predominantly develops in childhood and young adulthood and accounts for approximately 5–10% of all diabetes cases. It is caused by the body’s immune system destroying pancreatic beta...
-
Product Insights
Diabetic Retinopathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Diabetic Retinopathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$3,450 | October 2024 Diabetic Retinopathy Clinical Trial Report Overview A total of 818 diabetic retinopathy clinical trials were conducted as of October 2024. The diabetic retinopathy clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      North America ·      ...
-
Product Insights
Diabetic Retinopathy - Drugs In Development, 2024 Diabetic Retinopathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. The Diabetic Retinopathy drugs in development market research report provide comprehensive information on...
-
Product Insights
Diabetic Macular Edema - Drugs In Development, 2024 Diabetic Macular Edema - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if left untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market...
-
Product Insights
Diabetic Foot Ulcers - Drugs In Development, 2024 Diabetic Foot Ulcers - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Foot Ulcers – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic foot ulcers are sores that occur on the feet of people with type 1 and type 2 diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg; pain; walking with difficulty; black, blue, or red discoloration of the feet; cold feet; and fever, skin redness, or swelling, or other signs of infection. The predisposing factors include diabetic...
-
Product Insights
Diabetic Nephropathy - Drugs In Development, 2024 Diabetic Nephropathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Nephropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic nephropathy is damage to the kidney occurring due to diabetes. It is characterized by albuminuria, a reduction in glomerular filtration rate (GFR), and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels, and smoking. This condition is managed by medication and dietary modification. The Diabetic Nephropathy drugs in development market research report provide comprehensive information on the...
-
Product Insights
Diabetic Neuropathy - Drugs In Development, 2024 Diabetic Neuropathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain. Predisposing factors include obesity, hypertension, high lipid and sugar levels, and smoking. It may be managed by medication and dietary modification. The Diabetic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Diabetic Peripheral Neuropathy - Drugs In Development, 2024 Diabetic Peripheral Neuropathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet; pain or discomfort in the feet or legs, including prickly, sharp pain or burning feet; muscle weakness and loss of muscle tone in the feet and lower...
-
Product Insights
Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024 Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.